Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- QNST +12.5%, KEM +12%, QRVO +11.9%, OTEX +11.5%, EBAY +10.3%, NOK +9.6%, TUES +6.9%, ST +6.7%, VRTX +6.2%, (selects VX-659 and VX-445, two next-generation correctors for phase 3 development as part of two different triple combination regimens ), QGEN +4.5%, (also to acquire STAT-Dx), T +3.7%, USG +3.5%, MKSI +3.4%, ESIO +2.5%, FB +2.5%, NOG +2.5%, MPC +2.4%, ALGT +2%, X +1.9%, VLO +1.8%, DGX +1.6%, UN +1.3%, MA +1.3%, AME +1%, TWX +0.9%
Other news:
- LTBR +25.7% (awarded key patents in Europe and China for innovative metallic fuel design that each extend through 2034)
- ZN +18% ( launches new $5 per share Unit Program of limited duration during the month of February)
- SNDX +6.4% (announces clinical collaboration with AstraZeneca)
- VRTX +6.2% (reports Phase 2 data showed mean absolute improvements in ppFEV1 of up to 13.3 and 13.8 percentage points for VX-659 and VX-445)
- P +3.1% (announced organizational restructuring that shifts resources to focus on ad-tech and audience development efforts)
- GPRO +1.3% (GoPro rolls out enhanced subscription service)
- SGEN +1% (prices 11,538,461 common stock offering at $52.00/share)
- TEVA +0.8% (discloses entry into settlement agreement and mutual releases with Allergan)
Analyst comments:
- WLL +2.5% (upgraded to Neutral from Sell at Goldman)
- PBR +2.5% (upgraded to Neutral from Sell at Goldman)
- TTWO +2.4% (initiated with a Overweight at Morgan Stanley)
- STO +1.3% (upgraded to Neutral from Sell at Goldman)